Tempus AI (NASDAQ:TEM) Shares Down 4.1% on Insider Selling

Tempus AI, Inc. (NASDAQ:TEMGet Free Report)’s stock price dropped 4.1% during trading on Monday following insider selling activity. The stock traded as low as $48.08 and last traded at $49.31. Approximately 8,476,573 shares changed hands during mid-day trading, a decline of 8% from the average daily volume of 9,223,558 shares. The stock had previously closed at $51.40.

Specifically, CEO Eric P. Lefkofsky sold 85,788 shares of Tempus AI stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $53.39, for a total transaction of $4,580,221.32. Following the completion of the transaction, the chief executive officer now owns 5,771,787 shares in the company, valued at approximately $308,155,707.93. This trade represents a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Eric P. Lefkofsky sold 476,209 shares of the business’s stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $49.84, for a total value of $23,734,256.56. Following the sale, the chief executive officer now owns 6,502,643 shares of the company’s stock, valued at approximately $324,091,727.12. This represents a 6.82 % decrease in their position. The disclosure for this sale can be found here.

Analysts Set New Price Targets

Several research firms have commented on TEM. Stifel Nicolaus lowered shares of Tempus AI from a “buy” rating to a “hold” rating and raised their target price for the company from $45.00 to $65.00 in a report on Monday, November 11th. Wolfe Research initiated coverage on shares of Tempus AI in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 target price on the stock. Loop Capital reduced their target price on Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a report on Tuesday, January 14th. Needham & Company LLC reissued a “buy” rating and issued a $56.00 price objective on shares of Tempus AI in a research report on Tuesday, January 14th. Finally, Guggenheim started coverage on shares of Tempus AI in a research report on Monday, December 9th. They set a “buy” rating and a $74.00 target price on the stock. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $56.36.

Check Out Our Latest Research Report on TEM

Tempus AI Trading Down 1.6 %

The business has a 50 day moving average price of $44.26 and a two-hundred day moving average price of $47.95. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

Institutional Investors Weigh In On Tempus AI

Large investors have recently made changes to their positions in the business. Kovitz Investment Group Partners LLC bought a new position in Tempus AI in the 3rd quarter worth about $1,367,000. Sumitomo Mitsui Trust Group Inc. grew its position in Tempus AI by 1,591.2% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock valued at $68,922,000 after acquiring an additional 1,145,698 shares during the last quarter. Captrust Financial Advisors bought a new stake in Tempus AI in the third quarter worth $2,726,000. Sigma Planning Corp bought a new position in Tempus AI during the 3rd quarter worth approximately $1,323,000. Finally, Dakota Wealth Management purchased a new stake in Tempus AI during the 3rd quarter valued at $1,185,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

Tempus AI Company Profile

(Get Free Report)

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

Read More

Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.